David Huang

“I know in the past you had talked about how the uptake and penetration was going in academic versus community practices, and so I was just wondering what the latest is there in terms of how penetration is looking in those segments and where there might be more room to grow.”

“You know, it was a pleasure working with you, and I wish you only the best in your next chapter.”

“I want to ask about the upcoming POC data for 921628 programs in Alzheimer's. How should we think about the bar that you would use to justify moving these programs forward based on that data?”

“So I just wanted to ask about so maybe two questions. So, for focal epilepsy for the adolescent population there, what additional work would be required to get a label and extend down to adolescent patients?”

“So I just wanted to ask first on, I guess, latest thoughts, maybe around the relative market size and opportunity for NT1, NT2, and IH? And I think, you know, the thinking is maybe the IH market is perhaps bigger than, you know, some of the epidemiology historically has suggested.”